Heart Drug Spotlights Troubling Trends In Drug Marketing
Critics worry the marketing of Vascepa, a purified fish oil product, could prove a fish story.
FDA
401-420 of 478 results
-
-
Hidden Drugs And Danger Lurk In Over-The-Counter Supplements, Study Finds
Dieters and gym rats, beware. Some dietary supplements promising weight loss or more muscle may contain active ingredients not listed on the label that fly under the radar of the Food and Drug Administration. The California Department of Public Health analyzed public data maintained by the FDA to suss out trends among tainted products, raising red flags.
By Rachel Bluth -
Podcast: KHN’s ‘What The Health?’ Falling Premiums And Rising Political Tensions
In this episode of KHN’s “What the Health?” Mary Agnes Carey of Kaiser Health News, Rebecca Adams of CQ Roll Call, Anna Edney of Bloomberg News and Julie Appleby of Kaiser Health News discuss the Trump administration’s announcement that average premium prices are falling on the Obamacare marketplaces, the effort by Senate Democrats to reverse rules on short-term health insurance and the focus on protections for people with preexisting conditions in the run-up to midterm elections.
-
The Feds’ Termination Of A Tiny Contract Inflames Bitter Fight Over Fetal Tissue
Just weeks before midterm elections, a move by federal health officials spotlights a contentious issue: the use of human fetal tissue in research. Here’s what you need to know to understand the debate.
-
Podcast: KHN’s ‘What The Health?’ Some Things Old, Some Things New
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Rebecca Adams of CQ Roll Call, Margot Sanger-Katz of The New York Times and Kimberly Leonard of the Washington Examiner discuss final action on bills in Congress to address the opioid epidemic and fund federal health agencies. They also look at new efforts by the Food and Drug Administration to crack down on teen nicotine use.
-
Drugmakers Play The Patent Game To Lock In Prices, Block Competitors
Pharmaceutical companies like Purdue Pharma, maker of OxyContin, often win patents for incremental changes with debatable value. Now there’s a twist involving an opioid treatment.
-
Buried In Congress’ Opioid Bill Is Protection For Personal Drug Imports
The protection is a win for people who get their needed, legitimate drugs from overseas.
-
As States Try To Rein In Drug Spending, Feds Slap Down One Bold Medicaid Move
Medicaid drug spending doubled in five years in Massachusetts. The state wanted to exclude expensive drugs that weren't proven to work better than existing alternatives from its Medicaid plan, but the federal government blocked the effort.
-
Half As Many People Are Trying Heroin, But Marijuana Use Grows
An annual government survey of drug use and health shows a dramatic drop in the number of people who tried heroin but an uptick in pot use.
By Jenny Gold -
Podcast: KHN’s ‘What The Health?’ A Detour On A Smoking Off-Ramp
In this episode of KHN’s “What the Health?” Sarah Jane Tribble of Kaiser Health News, Stephanie Armour of The Wall Street Journal, Kimberly Leonard of the Washington Examiner and Rebecca Adams of CQ Roll Call talk about the Food and Drug Administration’s latest actions to address teenagers’ use of e-cigarettes, Arkansas’ Medicaid work requirements and news about the uninsured from the latest federal Census report.
-
Cancer, Schmancer. In California, Coffee Is King
The Golden State, with the rare support of the Trump administration, is seeking to circumvent a court order that would require cancer warnings in every establishment that sells a hot cup of Joe.
-
Podcast: KHN’s ‘What The Health?’ Opioids, EpiPens And Health Funding
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Alice Ollstein of Talking Points Memo, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico discuss Senate action on health funding and opioid legislation, the state of the individual insurance market and consternation over expiration dates on EpiPens, the self-injected allergy remedy. Also, could an otter with asthma signal a potential public health crisis?
-
Biorhythms And Birth Control: FDA Stirs Debate By Approving ‘Natural’ App
Critics worry about the message federal officials are sending by approving a new birth control option, which uses a mobile phone app for women to track their body temperature and menstrual cycle to avoid pregnancy. But the more choices the better, some reproductive health experts say.
-
Trump Administration Sinks Teeth Into Paring Down Drug Prices, On 5 Key Points
Instead of waiting for congressional action, federal regulators are looking at a series of actions to spur competition and drive down the cost of medicines.
-
Pharmacy-Made Pain Creams Flagged On Fears Of Medicare Fraud And Risk
Inspector general identifies possible problems in nearly 23 percent of pharmacies that bill Medicare for blended creams, gels and lotions.
-
Podcast: KHN’s ‘What The Health?’ Congress And Health Care. Again.
In this episode of KHN’s “What the Health?” Julie Rovner of Kaiser Health News, Anna Edney of Bloomberg News, Alice Ollstein of Talking Points Memo and Kimberly Leonard of the Washington Examiner talk about the new push on health legislation by Republicans in the House, as well as developments on Medicaid work requirements, drug prices and the fate of children separated from their parents at the U.S.-Mexican border. Plus, for extra credit, the panelists offer their favorite health stories of the week.
-
Must-Reads Of The Week From Brianna Labuskes
KHN’s newsletter editor, Brianna Labuskes, wades through hundreds of health articles from the week so you don’t have to.
-
Top Policy Expert’s Ties To Giant Drugmaker Often Go Unstated
Dr. Mark McClellan joined Johnson & Johnson’s board of directors after leaving the FDA, but the connection often isn’t mentioned in research papers or public events.
-
Bubble Pop? Brownie Batter? Vapes’ Added Flavors Fuel E-Cig Debate
Vaping is becoming increasingly popular in the United States, especially among young people. This fact is triggering an unexpected divide within the public health community and complicating efforts to regulate the industry.
-
Drugmakers Blamed For Blocking Generics Have Jacked Up Prices And Cost U.S. Billions
The Trump administration is shaming brand-name drugmakers who refuse to sell samples so generics can be made from their products.